Tamari, Roni; McLornan, Donal P; Ahn, Kwang Woo; Estrada-Merly, Noel; Hernández-Boluda, Juan Carlos; Giralt, Sergio; Palmer, Jeanne; ... Saber, Wael; + view all Tamari, Roni; McLornan, Donal P; Ahn, Kwang Woo; Estrada-Merly, Noel; Hernández-Boluda, Juan Carlos; Giralt, Sergio; Palmer, Jeanne; Gale, Robert Peter; Defilipp, Zachariah; Marks, David I; Van der Poel, Marjolein; Verdonck, Leo F; Battiwalla, Minoo; Diaz, Miguel Angel; Gupta, Vikas; Ali, Haris; Litzow, Mark Robert; Lazarus, Hillard M; Gergis, Usama; Bashey, Asad; Liesveld, Jane; Hashmi, Shahrukh; Pu, Jeffrey J; Beitinjaneh, Amer; Bredeson, Christopher; Rizzieri, David; Savani, Bipin N; Abid, Muhammad Bilal; Ganguly, Siddhartha; Agrawal, Vaibhav; Bacher, Vera Ulrike; Wirk, Baldeep; Jain, Tania; Cutler, Corey; Aljurf, Mahmoud; Kindwall-Keller, Tamila; Kharfan-Dabaja, Mohamed A; Hildebrandt, Gerhard C; Pawarode, Attaphol; Solh, Melhem M; Yared, Jean A; Grunwald, Michael R; Nathan, Sunita; Nishihori, Taiga; Seo, Sachiko; Scott, Bart L; Nakamura, Ryotaro; Oran, Betul; Czerw, Tomasz; Yakoub-Agha, Ibrahim; Saber, Wael; - view fewer (2023) A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Advances , 7 (15) pp. 3993-4002. 10.1182/bloodadvances.2023009886.

Preview

Text cibmtr score.pdf - Published Version Download (411kB) | Preview

Abstract

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item